Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Farmakoekonomika zdravljenja dislipedemij pri bolnikih z akutnim koronarnim sindromom = Pharmacoeconomics of dyslipidemia treatment in patients with acute coronary syndrome
    Cevc, Matija
    Cardiovascular diseases (CVD) are still among the leading causes of mortality and one of the most frequent reason for hospital admission in Slovenia. Hypercholesterolemia is the major risk factor for ... CVD. Treatment of hyperlipidemia and CVD represents important financial burden. With this analysis we tried to evaluate the cost effectiveness of dyslipidemia treatmentwhen compared to costs of major cardiovascular events (represented bycase of acute coronary syndrome - ACS). By lowering the LDL cholesterol withstatins for more than 1,5mmol/l in 1000 patients, 50 major cardiovascular events (CVE) would be prevented in primary prevention and 96 major CVE in secondary prevention. Also the number of hospital admission, the length of hospitalisation and the revascularisation rate would be reduced. To achieve the goal of reducing the LDL cholesterol for more than 1,5 mmol/l by the lowest cost statin the cost of treatment for 1000 patients in 5 years would amount to 214.087.150 SIT (893.377 ). By simplifying and taking into account only ACS as major CVE, primary prevention of 50 ACS in 5 years would cost 93.520.489 SIT (390.254,08 ) and secondary prevention of 96 ACS in 5 years would cost 161.073.484 SIT (618.395,81 ). This sum represents only basic costs of ACS treatment that would be doubled by incorporating staff salaries. Hundred and fifty eight subjects younger than 65 years old died in the year 2003 because of ischemic heart diseases. All these deaths could have been prevented if the patients had been adequately treated. With the use of methodof human resources it can be calculated that these deaths represent additional yearly cost of 3,76 billion SIT (15.69 million ). It seems that the treatment with statins is cost effective in primary as well as in secondary prevention.
    Vir: Slovenska kardiologija : znanstveno strokovna revija za področje srčno-žilne medicine. - ISSN 1581-8543 (Letn. 3, št. 1, 2006, str. 24-29)
    Vrsta gradiva - članek, sestavni del
    Leto - 2006
    Jezik - slovenski
    COBISS.SI-ID - 21311449

Vnos na polico